CD18 Antibody Application Blocks Unwanted Off-Target T Cell Activation Caused by Bispecific Antibodies.

CD18 T cell activation bispecific antibodies cytokine release syndrome immunotherapy

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
13 Sep 2021
Historique:
received: 22 07 2021
revised: 03 09 2021
accepted: 10 09 2021
entrez: 28 9 2021
pubmed: 29 9 2021
medline: 29 9 2021
Statut: epublish

Résumé

T cell-recruiting bispecific antibodies (bsAbs) are successfully used for the treatment of cancer. However, effective treatment with bsAbs is so far hampered by severe side effects, i.e., potentially life-threatening cytokine release syndrome. Off-target T cell activation due to binding of bispecific CD3 antibodies to T cells in the absence of target cells may contribute to excessive cytokine release. We report here, in an in vitro setting, that off-target T cell activation is induced by bsAbs with high CD3 binding affinity and increased by endothelial- or lymphoid cells that act as stimulating bystander cells. Blocking antibodies directed against the adhesion molecules CD18/CD54 or CD2/CD58 markedly reduced this type of off-target T cell activation. CD18 blockade-in contrast to CD2-did not affect the therapeutic activity of various bsAbs. Since CD18 antibodies have been shown to be safely applicable in patients, blockade of this integrin holds promise as a potential target for the prevention of unwanted off-target T cell activation and allows the application of truly effective bsAb doses.

Identifiants

pubmed: 34572822
pii: cancers13184596
doi: 10.3390/cancers13184596
pmc: PMC8467378
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Deutsche Krebshilfe
ID : 111828
Organisme : Germany's Excellence Strategy
ID : EXC 2180/1
Organisme : Deutsche Krebshilfe
ID : 70112914
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : Deutschen Konsortium für Translationale Krebsforschung
ID : n/a
Organisme : Deutsche Forschungsgemeinschaft
ID : SA1360/7-3
Organisme : Deutsche Forschungsgemeinschaft
ID : SA1360/9-1
Organisme : Wilhelm Sander-Stiftung
ID : 2007.115.3

Références

Trends Pharmacol Sci. 2003 Dec;24(12):640-7
pubmed: 14654305
Cell Mol Biol Lett. 2017 Feb 28;22:4
pubmed: 28536635
Nat Med. 2018 Jun;24(6):731-738
pubmed: 29808005
Proc Natl Acad Sci U S A. 1986 Jun;83(12):4479-83
pubmed: 3086885
Cell. 1994 Jan 28;76(2):301-14
pubmed: 7507411
Mol Ther. 2015 Apr;23(4):648-55
pubmed: 25578618
J Exp Med. 1991 Jul 1;174(1):253-67
pubmed: 1676048
Clin Colorectal Cancer. 2016 Dec;15(4):345-351
pubmed: 27591895
J Clin Oncol. 2011 Jun 20;29(18):2493-8
pubmed: 21576633
Nature. 1989 Oct 19;341(6243):619-24
pubmed: 2477710
Clin Pharmacol Ther. 1998 Sep;64(3):339-46
pubmed: 9757158
N Engl J Med. 2006 Mar 2;354(9):924-33
pubmed: 16510746
Eur J Immunol. 1991 Oct;21(10):2431-5
pubmed: 1655465
J Biol Chem. 2002 Dec 27;277(52):50255-62
pubmed: 12368274
EMBO Mol Med. 2021 Feb 5;13(2):e11902
pubmed: 33372710
Am J Cardiol. 2001 Sep 1;88(5):482-7
pubmed: 11524054
Br J Cancer. 2000 Jan;82(2):472-9
pubmed: 10646907
Science. 2008 Aug 15;321(5891):974-7
pubmed: 18703743
Immunodefic Rev. 1988;1(1):39-54
pubmed: 3078709
Nature. 1985 Apr 18-24;314(6012):628-31
pubmed: 2859527
Int J Cancer. 1996 May 16;66(4):477-83
pubmed: 8635863
Nature. 1985 Jul 25-31;316(6026):354-6
pubmed: 3160953
Circulation. 2001 Dec 4;104(23):2778-83
pubmed: 11733394
Sci Transl Med. 2019 Sep 4;11(508):
pubmed: 31484792
Immunol Today. 1988 Sep;9(9):257-60
pubmed: 2978374
J Am Coll Cardiol. 2002 Oct 2;40(7):1199-204
pubmed: 12383565
N Engl J Med. 2012 May 17;366(20):1870-80
pubmed: 22591293
J Trauma. 2000 Oct;49(4):611-9; discussion 619-20
pubmed: 11038077
Br J Cancer. 1994 Oct;70(4):652-61
pubmed: 7917912
Oncol Res. 2015;22(2):117-21
pubmed: 25706398
Front Immunol. 2018 May 03;9:952
pubmed: 29774029
Cytotherapy. 2017 Jul;19(7):867-880
pubmed: 28506444
Clin Cancer Res. 1997 Jan;3(1):81-5
pubmed: 9815541
Nat Med. 2018 Jun;24(6):739-748
pubmed: 29808007
Clin Exp Immunol. 2017 Nov;190(2):258-267
pubmed: 28714582
Nature. 1989 Dec 14;342(6251):811-3
pubmed: 2574829
Nat Rev Immunol. 2016 Mar;16(3):193-201
pubmed: 26852928

Auteurs

Joseph Kauer (J)

German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ) Partner Site Tübingen, Department of Immunology, Interfaculty Institute for Cell Biology, University of Tübingen, 72076 Tübingen, Germany.
Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, 72076 Tübingen, Germany.
Department of Oncology and Hematology, University Clinic Heidelberg, 69118 Heidelberg, Germany.

Fabian Vogt (F)

German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ) Partner Site Tübingen, Department of Immunology, Interfaculty Institute for Cell Biology, University of Tübingen, 72076 Tübingen, Germany.

Ilona Hagelstein (I)

Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, 72076 Tübingen, Germany.
DFG Cluster of Excellence 2180 'Image-Guided and Functional Instructed Tumor Therapy' (iFIT), Eberhard Karls University, 72076 Tübingen, Germany.

Sebastian Hörner (S)

German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ) Partner Site Tübingen, Department of Immunology, Interfaculty Institute for Cell Biology, University of Tübingen, 72076 Tübingen, Germany.

Melanie Märklin (M)

Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, 72076 Tübingen, Germany.
DFG Cluster of Excellence 2180 'Image-Guided and Functional Instructed Tumor Therapy' (iFIT), Eberhard Karls University, 72076 Tübingen, Germany.

Stefanie Maurer (S)

Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, 72076 Tübingen, Germany.
DFG Cluster of Excellence 2180 'Image-Guided and Functional Instructed Tumor Therapy' (iFIT), Eberhard Karls University, 72076 Tübingen, Germany.
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Helmut R Salih (HR)

Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, 72076 Tübingen, Germany.
DFG Cluster of Excellence 2180 'Image-Guided and Functional Instructed Tumor Therapy' (iFIT), Eberhard Karls University, 72076 Tübingen, Germany.

Gundram Jung (G)

German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ) Partner Site Tübingen, Department of Immunology, Interfaculty Institute for Cell Biology, University of Tübingen, 72076 Tübingen, Germany.

Latifa Zekri (L)

German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ) Partner Site Tübingen, Department of Immunology, Interfaculty Institute for Cell Biology, University of Tübingen, 72076 Tübingen, Germany.
Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, 72076 Tübingen, Germany.
DFG Cluster of Excellence 2180 'Image-Guided and Functional Instructed Tumor Therapy' (iFIT), Eberhard Karls University, 72076 Tübingen, Germany.

Classifications MeSH